3-(4-Hydroxy-3-methoxyphenyl) 酸通过GPR41促进肝脏脂质代谢的改善
Ryuji Ohue-Kitano1,2,3, Yuki Masujima4, Shota Nishikawa5
1Laboratory of Molecular Neurobiology, Graduate School of Biostudies, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. ohue.ryuji.8e@kyoto-u.ac.jp.
Scientific reports
|December 1, 2023
概括
3-(4-基-3-甲基) 酸 (HMPA),一种植物代谢物,激活GPR41受体. 这种激活有助于抗肥胖作用,并通过促进脂质分解来改善脂肪肝,为代谢障碍治疗提供新的途径.
科学领域:
- 代谢学 代谢学 代谢学
- 肠道微生物组研究研究
- 分子药理学分子药理学
背景情况:
- 3-(4--3-甲基) 酸 (HMPA) 是一种由植物化合物衍生的肠道微生物代谢物.
- HMPA与潜在的健康益处有关,包括抗糖尿病和抗癌作用.
- 人们尚未完全理解HMPA生物可访问性,生物可用性和代谢调节的精确机制.
研究的目的:
- 为了识别和描述HMPA的特定受体.
- 阐明HMPA在代谢平衡中的作用背后的分子机制.
- 探索HMPA在治疗代谢障碍方面的潜力.
主要方法:
- 受体结合测试以确定HMPA亲和力.
- 细胞和动物模型研究代谢效应.
- 对脂质代谢途径的分析.
主要成果:
- 鉴定和表征了HMPA的特定GPR41受体,其亲和力比其前体更高.
- 证明HMPA激活GPR41对于抗肥胖作用至关重要.
- 显示了HMPA在通过刺激脂质代谢来改善肝硬化症中的作用.
结论:
- 特别地,HMPA针对并激活GPR41受体.
- 通过HMPA激活GPR41,可以显著改善抗肥胖和肝肥胖症.
- 这些发现支持开发基于HMPA的功能性食品和针对代谢障碍的针对GPR41的药物.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
5.6K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
Overview of Fatty Acid Metabolism
30.7K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
30.7K
IP3/DAG Signaling Pathway
12.1K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
671
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
671
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
41
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
41
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329


